Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding: the underlying causes of neurodegenerative and other rare diseases.Their therapeutic approaches elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death. Chaperone’s unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of protein misfolding disease and clinical evaluation propel their therapeutic discovery programs forward.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 6, 2016 | Grant | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | — | Grant |